AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML. However, accelera...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Weisberg, E, Manley, P, Mestan, J, Cowan-Jacob, S, Ray, A, Griffin, J D
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2006
Konular:
Minireview
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361347/
https://ncbi.nlm.nih.gov/pubmed/16721371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603170
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller